It has been a pivotal year for Proteomics International Laboratories Ltd (ASX:PIQ), with the signing of a landmark deal to bring our PromarkerD test for diabetic kidney disease to patients in the United States.
Apiam Animal Health Limited (ASX:AHX) today announced a market update ahead of the release of its financial results for the year ended 30 June 2023 (FY23).
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at the 17th Bioshares Biotech Summit on 25 July 2023.
Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 30 June 2023 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) has been invited to present the latest results from its novel blood test for oesophageal adenocarcinoma at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada, 8-10 September 2023.
Bluechiip Limited (ASX:BCT) (FRA:1BL) is pleased to confirm the successful completion of its share purchase plan ("SPP") first announced on Friday, 5 May 2023, raising $727,500.
In this interview, Dr. Richard Lipscombe, Managing Director of Proteomics International Laboratories Limited (ASX:PIQ), talks about the agreement recently entered into with Sonic Healthcare (USA).
